Market Size of South America Ovarian Cancer Diagnostics and Therapeutics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 9.20 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
South America Ovarian Cancer Diagnostics & Therapeutics Market Analysis
The rising incidences of ovarian cancer are one of the primary drivers for the market. The cancer burden is increasing, owing to factors such as the aging population, poor diet, smoking, and physical inactivity. According to Globocan, in 2018, there were around 243,588 deaths due to cancer in Brazil. Ovarian cancer (OC) is the most common cancer among women. OC has a high mortality rate and is difficult to diagnose. Due to its silent progression, it is contributing to the high mortality rate. Thus, due to the increasing incidence of ovarian cancer, the market for cancer diagnostics and therapeutics is expected to see stable growth in South America. Additionally, the rising geriatric population and increase in healthcare expenditure also contribute to the growth of the market.
South America Ovarian Cancer Diagnostics & Therapeutics Industry Segmentation
As per the scope of the report, Ovarian cancer is a type of cancer that begins in the ovaries. There are several types of ovarian cancer, among which Epithelial ovarian cancer is the most common type of ovarian cancer. The report covers various diagnostic and therapeutics used in the treatment of ovarian cancer.
| By Cancer Type | |
| Epithelial Ovarian Tumors | |
| Ovarian Germ Cell Tumors | |
| Others |
| By Modality | ||||||||
| ||||||||
|
| Geography | |||||
|
South America Ovarian Cancer Diagnostics and Therapeutics Market Size Summary
The South America ovarian cancer diagnostics and therapeutics market is experiencing growth driven by the increasing incidence of ovarian cancer, which is the most common cancer among women in the region. Factors such as an aging population, poor dietary habits, smoking, and physical inactivity are contributing to the rising cancer burden. The high mortality rate associated with ovarian cancer, due to its silent progression and challenging diagnosis, underscores the need for effective diagnostics and therapeutics. The market is supported by advancements in healthcare expenditure and the geriatric population's growth. Diagnostic methods such as biopsy, blood tests, ultrasound, PET, and CT scans are integral to the market, with CT machines, particularly those with robot-assisted surgical systems, enhancing surgical outcomes and driving market expansion.
The competitive landscape of the South America ovarian cancer diagnostics and therapeutics market is moderately populated with global players like AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, GlaxoSmithKline, Johnson & Johnson, and Siemens AG. These companies are pivotal in shaping the market dynamics through their innovative approaches and technological advancements. The market is expected to witness further penetration by more companies, driven by ongoing technological innovations. The preference for CT machines due to their ability to improve imaging and surgical outcomes is anticipated to propel market growth over the forecast period.
South America Ovarian Cancer Diagnostics and Therapeutics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Incidences of Ovarian Cancer
-
1.2.2 Rising Geriatric Population
-
1.2.3 Increase in Healthcare Expenditure
-
-
1.3 Market Restraints
-
1.3.1 Lack of Awareness
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Cancer Type
-
2.1.1 Epithelial Ovarian Tumors
-
2.1.2 Ovarian Germ Cell Tumors
-
2.1.3 Others
-
-
2.2 By Modality
-
2.2.1 Diagnosis
-
2.2.1.1 Biopsy
-
2.2.1.2 Blood Tests
-
2.2.1.3 Ultrasound
-
2.2.1.4 PET
-
2.2.1.5 CT Scan
-
2.2.1.6 Other Diagnosis
-
-
2.2.2 Therapeutics
-
2.2.2.1 Chemotherapy
-
2.2.2.2 Radiation Therapy
-
2.2.2.3 Immunotherapy
-
2.2.2.4 Hormonal Therapy
-
2.2.2.5 Others
-
-
-
2.3 Geography
-
2.3.1 South America
-
2.3.1.1 Brazil
-
2.3.1.2 Argentina
-
2.3.1.3 Rest of South America
-
-
-
South America Ovarian Cancer Diagnostics and Therapeutics Market Size FAQs
What is the current South America Ovarian Cancer Diagnostics and Therapeutics Market size?
The South America Ovarian Cancer Diagnostics and Therapeutics Market is projected to register a CAGR of 9.20% during the forecast period (2024-2029)
Who are the key players in South America Ovarian Cancer Diagnostics and Therapeutics Market?
AstraZeneca plc, F. Hoffman-La Roche Ltd, GlaxoSmithKline plc , Johnson & Johnson and Siemens AG are the major companies operating in the South America Ovarian Cancer Diagnostics and Therapeutics Market.
